Release Date: April 27, 2011
The purpose of this Notice is to clarify the intention of RFA-DA-12-003 (http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-12-003.html) and RFA-DA-12-004 (http://grants1.nih.gov/grants/guide/rfa-files/RFA-DA-12-004.html) to ensure that applicants understand the goals of the FOA.
This initiative is concerned with understanding the placebo effect, its mechanisms and its measurement. We are not interested in the measurement of placebo responding within the context of a randomized clinical trial that has as its primary goal the assessment of a therapeutic intervention. That is, free standing clinical trials (of any type) will be considered not responsive and will not be reviewed. However, if the primary goal of an application is to determine the mechanism of the placebo response, and it is necessary to do this within the context of a randomized clinical trial design, this is acceptable. In addition, we welcome secondary analyses that examine moderators and mediators of the placebo effect using anonymized datasets available to the research community.
All other aspects of the FOA remain unchanged.
Please direct all inquiries to:
Dr. Paul Schnur
National Institute on Drug Abuse (NIDA)
Telephone: 301- 435-1316
Dr. John Glowa
National Center for Complementary and Alternative Medicine (NCCAM)
Dr. Joanne Fertig
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
Office of Extramural
National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
Department of Health
and Human Services (HHS)